Dr. Sumit Subudhi (MD Anderson) leads a discussion on the latest available immunotherapies for prostate cancer patients. #CRIsummit #immunotherapy #pcsm
[ Ссылка ]

As the second most common male cancer in the world, roughly 1.3 million people receive a prostate cancer diagnosis each year. In its early stages, prostate cancer is highly treatable, but when advanced, effective treatments are limited. That’s where cancer immunotherapy offers new hope. There are already two FDA-approved immunotherapies—a therapeutic cancer vaccine and a checkpoint inhibitor—and many more promising treatments in clinical trials. [ Ссылка ]

In this video, Dr. Subudhi addresses:
- Prostate tumor microenvironment
- Immune checkpoint therapies, including PD-1/PD-L1 and CTLA-4 checkpoint inhibitors
- Combination therapies, using chemotherapy, immunotherapy, targeted therapy, and/or hormone therapy
- Overall health of prostate cancer patient, including diet, exercise, and age
- Tumor mutational burden and genomic sequencing
- Cancer immunotherapy clinical trials
- Preventive vs therapeutic cancer vaccines
- Impact of COVID-19 on cancer patient care
- Side effects of cancer immunotherapy
- Treatment regimen decisions, including how a drug is administered or the length of time a patient is on it
- BiTEs, or bi-specific T cell engager therapies
- Family history of cancer

Dr. Sumit Subudhi is a medical oncologist and immunologist at the University of Texas MD Anderson Cancer Center whose research focuses on the mechanisms and pathways within the immune system that are responsible for tumor rejection and clinical benefit. His focus is on investigating optimal combinations of immune checkpoint blockade-based therapies and on developing immunological biomarkers to predict treatment responses, with the hope of ultimately producing durable and even curative responses in patients with prostate cancer. Dr. Subudhi was awarded the Prostate Cancer Foundation Young Investigator Award in 2014 to pursue these studies. He has also been investigating the immunological differences between primary prostate cancer and the bone metastasis microenvironment. He is currently the study chair for a Cancer Research Institute and Parker Institute for Cancer Immunotherapy platform clinical trial that is simultaneously evaluating multiple treatment combinations in patients with metastatic castration-resistant prostate cancer. [ Ссылка ]

The 2020 CRI Virtual Immunotherapy Patient Summit is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization that is dedicated to harnessing our immune system's power to control and potentially cure all cancers. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field's leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. Our Mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. [ Ссылка ]

Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.

свернуть